Abstract:
A compound represented by the following formula, a salt thereof or a hydrate of the foregoing is useful as a pharmaceutical composition for treating esophageal cancer treating esophageal cancer. 
     
       
                 
         
             
             
         
       
     
     [R 1  represents a 3- to 10-membered non-aromatic heterocyclic group or the like; R 2  and R 3  represent hydrogen; R 4 , R 5 , R 6 , and R 7  may be the same or different and each represents hydrogen, halogen, C 1-6  alkyl or the like; R 8  represents hydrogen or the like; R 9  represents a 3- to 10-membered non-aromatic heterocyclic group or the like; n represents an integer of 1 or 2; X represents —CH═, nitrogen or the like.]

Description:
TECHNICAL FIELD 
       [0001]    The present invention relates to a pharmaceutical composition for treating esophageal cancer comprising a pyridine and pyrimidine derivative, a salt thereof or a hydrate of the foregoing having hepatocyte growth factor receptor inhibitory action, anti-tumor action, angiogenesis inhibitory action, cancer metastasis inhibitory action or the like. 
       BACKGROUND ART 
       [0002]    Overexpression of hepatocyte growth factor receptor (hereafter referred to as “HGFR”) is reported in various kinds of tumors such as a pancreatic cancer, a gastric cancer, a colorectal cancer, a breast cancer, a prostate cancer, a lung cancer, a renal cancer, a brain tumor, an ovarian cancer, an esophageal cancer (non-patent documents 1 and 5). HGFR expressed in these cancer cells is considered to be involved in cancer malignancy (aberrant growth, invasion or enhanced metastasis), because HGFR cause autophosphorylation of intracellular tyrosine kinase constitutively or upon stimulation by hepatocyte growth factor (hereafter referred to as HGF). 
         [0003]    It is also reported that HGFR is expressed in vascular endothelial cells and is involved in tumor angiogenesis since HGF stimulates HGFR to facilitate proliferation and migration of vascular endothelial cells (non-patent document 2). 
         [0004]    Furthermore, NK4, an antagonistic peptide for HGF, is reported to block HGF-HGFR signal to inhibit invasion of cancer cells and tumor angiogenesis (non-patent documents 3 and 4). 
         [0005]    Therefore, a compound having inhibitory activity against HGFR is expected to be useful as an anti-tumor agent, an angiogenesis inhibitor or an inhibitor for cancer metastasis. 
         [0006]    On the other hand, patent document 1 discloses low-molecular compounds having inhibitory activity against HGFR. 
         [0007]    [Patent document 1] WO 2007/023768 
         [0008]    [Non-patent document 1] Oncology Reports, 5, 1013-1024 (1998) 
         [0009]    [Non-patent document 2] Advances in Cancer Research, 67, 257-279 (1995) 
         [0010]    [Non-patent document 3] British Journal of Cancer, 84, 864-873 (2001) 
         [0011]    [Non-patent document 4] Cancer Sci., 94, 321-327 (2003) 
         [0012]    [Non-patent document 5] Oncogene, 25(3), 409-418 (2006) 
       DISCLOSURE OF THE INVENTION 
     Problems to be Solved by the Invention 
       [0013]    The object of the invention is to discover a pharmaceutical composition for treating esophageal cancer by inhibiting aberrant growth, morphological change and motility facilitation of cells via HGFR in vivo. 
       Means for Solving the Problems 
       [0014]    As a result of diligent studies, the inventors have discovered that a novel pyridine and pyrimidine derivative represented by the general formula (I) below, a salt thereof or a hydrate of the foregoing has excellent inhibitory action against HGFR, and completed the present invention. 
         [0015]    Namely, the present invention provides [1] to [24] below: 
         [0000]    [1] A pharmaceutical composition for treating esophageal cancer, comprising a compound represented by the following formula, a salt thereof or a hydrate of the foregoing: 
         [0000]    
       
                 
         
             
             
         
       
     
         [0016]    wherein R 1  represents a 3- to 10-membered non-aromatic heterocyclic group wherein the group is limited to a group having nitrogen as a ring constituent atom and the nitrogen having a bonding hand, or a group represented by the formula —NR 11a R 11b , wherein R 11a  and R 11b  may be the same or different and each represents hydrogen, C 1-6  alkyl, C 3-6  alkenyl, C 3-6  alkynyl, C 3-10  cycloalkyl, C 6-10  aryl, 5- to 10-membered heteroaryl or a 4- to 10-membered non-aromatic heterocyclic group, and R 11a  and R 11b  may be substituted with a substituent selected from Substituent Group A or Substituent Group B and R 1  may be substituted with a substituent selected from Substituent Group A or Substituent Group B; 
         [0017]    R 2  and R 3  represent hydrogen; 
         [0018]    R 4 , R 5 , R 6  and R 7  may be the same or different and each represents hydrogen, halogen, hydroxyl, cyano, trifluoromethyl, C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 1-6  alkoxy, amino, mono-C 1-6  alkylamino, di-C 1-6  alkylamino or a group represented by the formula —CO—R 12 , wherein R 12  represents hydrogen, hydroxyl, C 1-6  alkyl, C 1-6  alkoxy, amino, mono-C 1-6  alkylamino or di-C 1-6  alkylamino; 
         [0019]    R 8  represents hydrogen or C 1-6  alkyl; 
         [0020]    R 9  represents a 3- to 10-membered non-aromatic heterocyclic group wherein the group is limited to a group having nitrogen as a ring constituent atom and the nitrogen having a bonding hand, or a group represented by the formula —NR 11a R 11b , wherein R 11a  and R 11b  represent the same meaning as described above and R 9  may be substituted with a substituent selected from Substituent Group A or Substituent Group B; 
         [0021]    n represents an integer of 1 or 2; and 
         [0022]    X represents a group represented by the formula —C(R 10 )═ or nitrogen, wherein R 10  represents hydrogen, halogen, cyano, C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl or a group represented by the formula —CO—R 12 , wherein R 12  represents the same meaning as recited above; 
         [0023]    wherein Substituent Group A consists of halogen, hydroxyl, mercapto, nitro, cyano and oxo; 
         [0024]    wherein Substituent Group B consists of C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 3-10  cycloalkyl, C 6-10  aryl, 5- to 10-membered heteroaryl, a 3- to 10-membered non-aromatic heterocyclic group, C 1-6  alkoxy, C 3-6  alkenyloxy, C 3-6  alkynyloxy, C 3-10  cycloalkoxy, C 6-10  aryloxy, 5- to 10-membered heteroaryloxy, 4- to 10-membered non-aromatic heterocyclicoxy, C 1-6  alkylthio, C 3-6  alkenylthio, C 3-6  alkynylthio, C 3-10  cycloalkylthio, C 6-10  arylthio, 5- to 10-membered heteroarylthio, 4- to 10-membered non-aromatic heterocyclicthio and a group represented by the formula -T 1 -T 2 -T 3 , and each group in Substituent Group B may be substituted with a substituent selected from Substituent Group C, wherein T 1  represents a direct bond or C 1-6  alkylene, T 2  represents carbonyl, sulfinyl, sulfonyl, a group represented by the formula —C(═O)—O—, a group represented by the formula —O—C(═O)—, a group represented by the formula —SO 2 —O—, a group represented by the formula —O—SO 2 —, a group represented by the formula —NR T1 , a group represented by the formula —C(═O)—NR T1 —, a group represented by the formula —NR T1 —C(═O)—, a group represented by the formula —SO 2 —NR T1 — or a group represented by the formula —N T1 —SO 2 —, T 3  represents hydrogen, C 1-6  alkyl, C 3-6  alkenyl, C 3-6  alkynyl, C 3-10  cycloalkyl, C 6-10  aryl, 5- to 10-membered heteroaryl or a 4- to 10-membered non-aromatic heterocyclic group, and R T1  represents hydrogen or C 1-6  alkyl; and 
         [0025]    wherein Substituent Group C consists of halogen, hydroxyl, mercapto, nitro, cyano, oxo, C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 3-10  cycloalkyl, C 6-10  aryl, 5- to 10-membered heteroaryl, a 3- to 10-membered non-aromatic heterocyclic group, C 1-6  alkoxy, C 1-6  alkylthio, mono-C 1-6  alkylamino and di-C 1-6  alkylamino. 
         [0000]    [2] The pharmaceutical composition for treating esophageal cancer of [1], wherein R 1  represents a 3- to 10-membered non-aromatic heterocyclic group optionally substituted with a substituent selected from Substituent Group A or Substituent Group B recited in [1], wherein the group is limited to a group having nitrogen as a ring constituent atom and the nitrogen having a bonding hand.
 
[3] The pharmaceutical composition for treating esophageal cancer of [1], wherein R 1  represents a group represented by the formula (II):
 
         [0000]    
       
                 
         
             
             
         
       
     
         [0000]    wherein a represents an integer of 1 to 4;
 
or a group represented by the formula (III):
 
         [0000]    
       
                 
         
             
             
         
       
     
         [0000]    wherein b represents an integer of 1 to 3, and Z represents oxygen, sulfur, carbonyl, sulfonyl, or a group represented by the formula —NR Z —, wherein R Z  represents hydrogen or C 1-6  alkyl, and the groups represented by the formula (II) or (III) may be substituted with a substituent selected from Substituent Group A or Substituent Group B recited in [1].
 
[4] The pharmaceutical composition for treating esophageal cancer of [1], wherein R 1  represents azetidin-1-yl optionally substituted with a substituent selected from Substituent Group D, pyrrolidin-1-yl optionally substituted with a substituent selected from Substituent Group D, piperidin-1-yl optionally substituted with a substituent selected from Substituent Group D, azepan-1-yl optionally substituted with a substituent selected from Substituent Group D, piperazin-1-yl optionally substituted with a substituent selected from Substituent Group D, diazepan-1-yl optionally substituted with a substituent selected from Substituent Group D, morpholin-4-yl optionally substituted with a substituent selected from Substituent Group D, thiomorpholin-4-yl optionally substituted with a substituent selected from Substituent Group D, 1,1-dioxothiomorpholin-4-yl optionally substituted with a substituent selected from Substituent Group D,
 
         [0026]    wherein Substituent Group D consists of halogen, hydroxyl, mercapto, cyano, formyl, oxo, C 1-6  alkyl, C 3-10  cycloalkyl, C 1-6  alkoxy, amino, mono-C 1-6  alkylamino, di-C 1-6  alkylamino, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, diazepanyl and a group represented by -T 4 -T 5 , wherein T 4  represents carbonyl or sulfonyl, and T 5  represents C 1-6  alkyl, C 3-10  cycloalkyl, azetidinyl, pyrrolidinyl, piperidinyl, hydroxyl, C 1-6  alkoxy, amino, mono-C 1-6  alkylamino or di-C 1-6  alkylamino, 
         [0027]    where each group included in Substituent Group D may be substituted with hydroxyl, C 1-6  alkyl, di-C 1-6  alkylamino, azetidinyl or pyrrolidinyl. 
         [0000]    [5] The pharmaceutical composition for treating esophageal cancer of [1], wherein R 1  represent azetidin-1-yl optionally substituted with a substituent selected from Substituent Group E, pyrrolidin-1-yl optionally substituted with a substituent selected from Substituent Group E, piperidin-1-yl optionally substituted with a substituent selected from Substituent Group E, piperazin-1-yl optionally substituted with a substituent selected from Substituent Group E, diazepan-1-yl optionally substituted with a substituent selected from Substituent Group E or morpholin-4-yl optionally substituted with a substituent selected from Substituent Group E, 
         [0028]    wherein Substituent Group E consists of methyl, ethyl, dimethylamino, azetidinyl, pyrrolidinyl, piperidinyl and piperazinyl, where each group included in Substituent Group E may be substituted with hydroxyl, methyl, dimethylamino, azetidinyl, pyrrolidinyl or piperidinyl. 
         [0000]    [6] The pharmaceutical composition for treating esophageal cancer of [1], wherein R 1  represents azetidin-1-yl optionally substituted with a substituent selected from Substituent Group G, pyrrolidin-1-yl optionally substituted with a substituent selected from Substituent Group G, piperidin-1-yl optionally substituted with a substituent selected from Substituent Group G or piperazin-1-yl optionally substituted with a substituent selected from Substituent Group G, 
         [0029]    wherein Substituent Group G consists of dimethylamino, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, dimethylaminomethyl, dimethylaminoethyl, azetidin-1-ylmethyl, pyrrolidin-1-ylmethyl and piperidin-1-ylmethyl, 
         [0030]    where each group included in Substituent Group G may be substituted with methyl or dimethylamino. 
         [0000]    [6-1] The pharmaceutical composition for treating esophageal cancer of [1], wherein R 1  represents azetidin-1-yl optionally substituted with a substituent selected from Substituent Group G-1, pyrrolidin-1-yl optionally substituted with a substituent selected from Substituent Group G-1, piperidin-1-yl optionally substituted with a substituent selected from Substituent Group G-1 or piperazin-1-yl optionally substituted with a substituent selected from Substituent Group G-1, 
         [0031]    wherein Substituent Group G-1 consists of azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, dimethylaminomethyl, dimethyl aminoethyl, azetidin-1-ylmethyl, pyrrolidin-1-ylmethyl and piperidin-1-ylmethyl, 
         [0032]    where each group included in Substituent Group G-1 may be substituted with methyl or dimethylamino. 
         [0000]    [6-2] The pharmaceutical composition for treating esophageal cancer of [1], wherein R 1  represents azetidin-1-yl having dimethylamino, pyrrolidin-1-yl having dimethylamino or piperidin-1-yl having dimethylamino.
 
[6-3] The pharmaceutical composition for treating esophageal cancer of [1], wherein R 1  represents azetidin-1-yl optionally substituted with a substituent selected from Substituent Group G-2, pyrrolidin-1-yl substituted with a substituent selected from Substituent Group G-2 or piperidin-1-yl substituted with a substituent selected from Substituent Group G-2,
 
         [0033]    wherein Substituent Group G-2 consists of hydroxyl, methoxy, hydroxymethyl and dimethylaminoacetoxy. 
         [0000]    [6-4] The pharmaceutical composition for treating esophageal cancer of [1], wherein R 1  represents [2-(dimethylamino)ethyl]piperazin-1-yl, 4-pyrrolidin-1-ylpiperidin-1-yl, 4-[(dimethylamino)methyl]piperidin-1-yl, 4-azetidin-1-ylpiperidin-1-yl, 4-[3-(dimethylamino)azetidin-1-yl]piperidin-1-yl, 4-(4-methylpiperazin-1-yl)piperidin-1-yl, 4-(1-methylpiperidin-4-yl)piperazin-1-yl, 4-(1-methylazetidin-3-yl)piperazin-1-yl, 4-(dimethylamino)piperidin-1-yl, 4-(azetidin-1-ylmethyl)piperidin-1-yl, 4-(pyrrolidin-1-ylmethyl)piperidin-1-yl, (3S)-3-(dimethylamino)pyrrolidin-1-yl, (3R)-3-(dimethylamino)pyrrolidin-1-yl, azetidin-1-yl, pyrrolidin-1-yl, morpholin-4-yl, 4-methylpiperazin-1-yl, 3-hydroxyazetidin-1-yl, 1,3′-biazetidin-1′-yl, 3-(hydroxymethyl)azetidin-1-yl, 3-(dimethylamino)azetidin-1-yl, 3-[(dimethylamino)methyl] azetidin-1-yl, 4-hydroxypiperidin-1-yl, 4-(hydroxymethyl)piperidin-1-yl, (3R)-3-hydroxypyrrolidin-1-yl, (3S)-3-hydroxypyrrolidin-1-yl, 3-(azetidin-1-ylmethyl)azetidin-1-yl or 3-(2-dimethylaminoacetoxy)azetidin-1-yl.
 
[7] The pharmaceutical composition for treating esophageal cancer of [1], wherein R 1  represents a group represented by the formula —NR 11a R 11b , wherein R 11a  and R 11b  represent the same meaning as recited in [1].
 
[8] The pharmaceutical composition for treating esophageal cancer of [1], wherein R 1  represents a group represented by the formula —NR 11c R 11d , wherein R 11c  represents hydrogen or C 1-6  alkyl, and R 11d  represents C 1-6  alkyl or a group represented by the formula (IV):
 
         [0000]    
       
                 
         
             
             
         
       
     
         [0000]    wherein c represents an integer of 1 to 3, and Z 1  represents oxygen, sulfur, carbonyl, sulfonyl or a group represented by the formula —NR Z1 —, wherein R Z1  represents hydrogen or C 1-6  alkyl, and R 11d  may be substituted with a substituent selected from Substituent Group A or Substituent Group B recited in [1].
 
[9] The pharmaceutical composition for treating esophageal cancer of [1], wherein R 1  represents a group represented by the formula —NR 11e R 11f , wherein R 11e  represents hydrogen or C 1-6  alkyl, and R 11f  represents C 1-6  alkyl, pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl or tetrahydropyran-4-yl, and R 11f  may be substituted with a substituent selected from Substituent Group D recited in [4].
 
[10] The pharmaceutical composition for treating esophageal cancer of [1], wherein R 1  represents a group represented by the formula —NR 11g R 11h , wherein R 11g  represents hydrogen or methyl, and R 11h  represents n-propyl, n-butyl, pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl or tetrahydropyran-4-yl, and R 11h  may be substituted with a substituent selected from Substituent Group F,
 
         [0034]    wherein Substituent Group F consists of methyl, ethyl, n-propyl, acetyl, dimethylamino, diethylamino, azetidinyl, pyrrolidinyl and piperazinyl, 
         [0035]    where each group included in Substituent Group F may be substituted with methyl or dimethylamino. 
         [0000]    [11] The pharmaceutical composition for treating esophageal cancer of [1], wherein R 1  represents a group represented by the formula —N(CH 3 )R 11i , wherein R 11i  represents n-propyl, n-butyl, pyrrolidin-3-yl or piperidin-4-yl, and R 11i  may be substituted with a substituent selected from Substituent Group H, 
         [0036]    wherein Substituent Group H consists of dimethylamino, diethylamino, dimethylaminoethyl, dimethylaminopropyl and 1-methylazetidin-3-yl. 
         [0000]    [12] The pharmaceutical composition for treating esophageal cancer of [1], wherein R 1  represents a group represented by the formula —N(CH 3 )R 11j , wherein R 11j  represents 1-methylpiperidin-4-yl or 1-ethylpiperidin-4-yl.
 
[12-1] The pharmaceutical composition for treating esophageal cancer of [1], wherein R 1  represents a group represented by the formula —N(CH 3 )R 11k , wherein R 11k  represents 3-(dimethylamino)propyl or 1-[2-(dimethylamino)ethyl]piperidin-4-yl.
 
[12-2] The pharmaceutical composition for treating esophageal cancer of [1], wherein R 1  represents methyl(1-methylpiperidin-4-yl)amino, (1-ethylpiperidin-4-yl)(methyl)amino, [3-(dimethylamino)propyl](methyl)amino or {1-[2-(dimethylamino)ethyl]piperidin-4-yl}(methyl)amino.
 
[13] The pharmaceutical composition for treating esophageal cancer of any one of [1] to [12-2], wherein R 4 , R 5 , R 6  and R 7  may be the same or different and each represents hydrogen, halogen or C 1-6  alkyl.
 
[14] The pharmaceutical composition for treating esophageal cancer of any one of [1] to [13], wherein R 8  represents hydrogen.
 
[15] The pharmaceutical composition for treating esophageal cancer of any one of [1] to [14], wherein X represents a group represented by the formula —C(R 10a )=, wherein R 10a  represents hydrogen, halogen or cyano.
 
[16] The pharmaceutical composition for treating esophageal cancer of any one of [1] to [14], wherein X represents nitrogen.
 
[17] The pharmaceutical composition for treating esophageal cancer of any one of [1] to [16], wherein n represents 1.
 
[18] The pharmaceutical composition for treating esophageal cancer of any one of [1] to [17], wherein R 9  represents mono-C 1-6  alkylamino optionally substituted with a substituent selected from Substituent Group A or Substituent Group B recited in [1], mono-C 3-10  cycloalkylamino optionally substituted with a substituent selected from Substituent Group A or Substituent Group B recited in [1], mono-C 6-10  arylamino optionally substituted with a substituent selected from Substituent Group A or Substituent Group B recited in [1], mono-5- to 10-membered heteroarylamino optionally substituted with a substituent selected from Substituent Group A or Substituent Group B recited in [1] or mono-4- to 10-membered non-aromatic heterocyclic amino optionally substituted with a substituent selected from Substituent Group A or Substituent Group B recited in [1].
 
[19] The pharmaceutical composition for treating esophageal cancer of any one of [1] to [17], wherein R 9  represents mono-C 3-10  cycloalkylamino optionally substituted with a substituent selected from Substituent Group A or Substituent Group B recited in [1] or mono-C 6-10  arylamino optionally substituted with a substituent selected from Substituent Group A or Substituent Group B recited in [1].
 
[19-1] The pharmaceutical composition for treating esophageal cancer of any one of [1] to [17], wherein R 9  represents mono-C 3-10  cycloalkylamino optionally substituted with a substituent selected from Substituent Group I or mono-C 6-10  arylamino optionally substituted with a substituent selected from Substituent Group I,
 
         [0037]    wherein Substituent Group I consists of halogen, trifluoromethyl, cyano, C 1-6  alkyl and C 1-6  alkoxy. 
         [0000]    [19-2] The pharmaceutical composition for treating esophageal cancer of any one of [1] to [17], wherein R 9  represents cyclopentylamino optionally substituted with a substituent selected from Substituent Group I recited in [19-1], cyclohexylamino optionally substituted with a substituent selected from Substituent Group I recited in [19-1], cycloheptylamino optionally substituted with a substituent selected from Substituent Group I recited in [19-1] or phenylamino optionally substituted with a substituent selected from Substituent Group I recited in [19-1].
 
[20] The pharmaceutical composition for treating esophageal cancer of [1], wherein the compound represented by the formula (I) is
   (1) N-[4-({2-[({4-[2-(Dimethylamino)ethyl]piperazin-1-yl}carbonyl)amino]pyridin-4-yl}oxy)-2-fluorophenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (2) N-(2-Fluoro-4-{[2-({[methyl(1-methylpiperidin-4-yl)amino]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (3) N-(4-Fluorophenyl)-N′-{2-fluoro-4-[(2-{[(4-pyrrolidin-1-ylpiperidin-1-yl)carbonyl]amino}pyridin-4-yl)oxy]phenyl}cyclopropane-1,1-dicarboxamide,   (4) N-[4-({2-[({4-[(Dimethylamino)methyl]piperidin-1-yl}carbonyl)amino]pyridin-4-yl}oxy)-2-fluorophenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (5) N-{4-[(2-{[(4-Azetidin-1-ylpiperidin-1-yl)carbonyl]amino}pyridin-4-yl)oxy]-2-fluorophenyl}-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (6) N-[4-({2-[({4-[3-(Dimethylamino)azetidin-1-yl]piperidin-1-yl}carbonyl)amino]pyridin-4-yl}oxy)-2-fluorophenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (7) N-(2-Fluoro-4-{[2-({[4-(4-methylpiperazin-1-yl)piperidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (8) N-(2-Fluoro-4-{[2-({[4-(1-methylpiperidin-4-yl)piperazin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (9) N-(2-Fluoro-4-{[2-({[4-(1-methylazetidin-3-yl)piperazin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (10) N-(4-{[2-({[4-(Dimethylamino)piperidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}-2-fluorophenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (11) N-(4-{[2-({[4-(Azetidin-1-ylmethyl)piperidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}-2-fluorophenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (12) N-(4-Fluorophenyl)-N′-(2-fluoro-4-{[2-({[4-(pyrrolidin-1-ylmethyl)piperidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)cyclopropane-1,1-dicarboxamide,   (13) N-(4-{[2-({[(3S)-3-(Dimethylamino)pyrrolidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}-2-fluorophenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (14) N-(4-{[2-({[(3R)-3-(Dimethylamino)pyrrolidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}-2-fluorophenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (15) N-(2-Fluoro-4-{[2-({[methyl(1-methylpiperidin-4-yl)amino]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-phenylcyclopropane-1,1-dicarboxamide,   (16) N-(2-Fluoro-4-{[2-({[4-(4-methylpiperazin-1-yl)piperidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-phenylcyclopropane-1,1-dicarboxamide,   (17) N-[4-({2-[({4-[3-(Dimethylamino)azetidin-1-yl]piperidin-1-yl}carbonyl)amino]pyridin-4-yl}oxy)-2-fluorophenyl]-N′-phenylcyclopropane-1,1-dicarboxamide,   (18) N-(4-{[2-({[(1-Ethylpiperidin-4-yl)(methyl)amino]carbonyl}amino)pyridin-4-yl]oxy}-2-fluorophenyl)-N′-phenylcyclopropane-1,1-dicarboxamide,   (19) N-[4-({2-[(Azetidin-1-ylcarbonyl)amino]pyridin-4-yl}oxy)-2-fluorophenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (20) N-(4-Fluorophenyl)-N′-[2-fluoro-4-({2-[(pyrrolidin-1-ylcarbonyl)amino]pyridin-4-yl}oxy)phenyl]cyclopropane-1,1-dicarboxamide,   (21) N-{2-Fluoro-4-[(2-{[(3-hydroxyazetidin-1-yl)carbonyl]amino}pyridin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (22) N-[4-({2-[(1,3′-Biazetidin-1′-ylcarbonyl)amino]pyridin-4-yl}oxy)-2-fluorophenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (23) N-(2-Fluoro-4-{[2-({[3-(hydroxymethyl)azetidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (24) N-(4-{[2-({[3-(Dimethylamino)azetidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}-2-fluorophenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (25) N-[4-({2-[({3-[(Dimethylamino)methyl]azetidin-1-yl}carbonyl)amino]pyridin-4-yl}oxy)-2-fluorophenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (26) N-{2-Fluoro-4-[(2-{[(4-hydroxypiperidin-1-yl)carbonyl]amino}pyridin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (27) N-(2-Fluoro-4-{[2-({[4-(hydroxymethyl)piperidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (28) N-(2-Fluoro-4-{[2-({[(3R)-3-hydroxypyrrolidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (29) N-(2-Fluoro-4-{[2-({[(3S)-3-hydroxypyrrolidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (30) N-[4-({2-[(Azetidin-1-ylcarbonyl)amino]pyridin-4-yl}oxy)-2,5-difluorophenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (31) N-{2,5-Difluoro-4-[(2-{[(3-hydroxyazetidin-1-yl)carbonyl]amino}pyridin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (32) N-(2,5-Difluoro-4-{[2-({[4-(4-methylpiperazin-1-yl)piperidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (33) N-[2,5-Difluoro-4-({2-[({3-[(dimethylamino)methyl]azetidin-1-yl}carbonyl)amino]pyridin-4-yl}oxy)phenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (34) N-(2,5-Difluoro-4-{[2-({[methyl(1-methylpiperidin-4-yl)amino]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (35) N-{4-[(2-{[3-(Azetidin-1-ylmethyl)azetidin-1-ylcarbonyl]amino}pyridin-4-yl)oxy]-2,5-difluorophenyl}-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (36) N-(2,5-Difluoro-4-{[2-({[3-(hydroxymethyl)azetidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (37) N-{2,5-Difluoro-4-[(4-{[(3-hydroxyazetidin-1-yl)carbonyl]amino}pyrimidin-6-yl)oxy]phenyl}-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (38) N-[4-({4-[({3-[(Dimethylamino)methyl]azetidin-1-yl}carbonyl)amino]pyrimidin-6-yl}oxy)-2,5-difluorophenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (39) N-(2,5-Difluoro-4-{[4-({[3-(hydroxymethyl)azetidin-1-yl]carbonyl}amino)pyrimidin-6-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (40) N-(2,5-Difluoro-4-{[4-({[methyl(1-methylpiperidin-4-yl)amino]carbonyl}amino)pyrimidin-6-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (41) N-(2,5-Difluoro-4-{[4-({[4-(4-methylpiperazin-1-yl)piperidin-1-yl]carbonyl}amino)pyrimidin-6-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (42) N-(4-{[2-({[4-(Dimethylamino)piperidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}-2,5-difluorophenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (43) N-{2,5-Difluoro-4-[(2-{[(4-methylpiperazin-1-yl)carbonyl]amino}pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (44) N-{2,5-Difluoro-4-[(2-{[(4-hydroxypiperidin-1-yl)carbonyl]amino}pyridin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (45) N-{4-[(2-{[(4-Azetidin-1-ylpiperidin-1-yl)carbonyl]amino}pyridin-4-yl)oxy]oxy}-2,5-difluorophenyl}-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (46) N-(2,5-Difluoro-4-{[2-({[3-(2-dimethylaminoacetoxy)azetidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (47) N-(2,5-Difluoro-4-{[2-({[(3S)-3-hydroxypyrrolidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide or   (48) N-(2,5-Difluoro-4-{[2-({[(3R)-3-hydroxypyrrolidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.
 
[21] The pharmaceutical composition for treating esophageal cancer of [1], wherein the compound represented by the formula (I) is
   (1) N-(2-Fluoro-4-{[2-({[4-(4-methylpiperazin-1-yl)piperidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide   (2) N-[4-({2-[(azetidin-1-ylcarbonyl)amino]pyridin-4-yl}oxy)-2-fluorophenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide   (3) N-{2,5-Difluoro-4-[(2-{[(3-hydroxyazetidin-1-yl)carbonyl]amino}pyridin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide   (4) N-(2,5-Difluoro-4-{[2-({[4-(4-methylpiperazin-1-yl)piperidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide   (5) N-(2,5-Difluoro-4-{[2-({[methyl(1-methylpiperidin-4-yl)amino]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide or   (6) N-(2,5-Difluoro-4-{[2-({[3-(hydroxymethyl)azetidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.
 
[22] A method of treating esophageal cancer, comprising the step of administering to a patient suffering from esophageal cancer, the pharmaceutical composition for treating esophageal cancer of any one of [1] to [21]
 
[23] Use of the compound represented by the formula (I) above, the salt thereof or the hydrate of the foregoing for the preparation of a pharmaceutical composition for treating esophageal cancer.
 
[24] A compound represented by the formula (I) above, a salt thereof or a hydrate of the foregoing for use as a pharmaceutical composition for treating esophageal cancer.
   
 
       EFFECT OF THE INVENTION 
       [0092]    The compound of the present invention has inhibitory action against HGFR tyrosine kinase and inhibits proliferation of human cancer cells via HGFR activation as described in WO 2007/023768. The compound of the present invention also inhibits migration of human cancer cells. Furthermore, the compound of the present invention inhibits proliferation of vascular endothelial cells via HGF-HGFR signal. 
         [0093]    The compound of the present invention inhibits proliferation of human esophageal cancer cells (Pharmacological Test Example 1). Therefore, the compound of the present invention is useful as a pharmaceutical composition for treating esophageal cancer. 
         [0094]    However, the kind of cancers treated by the pharmaceutical composition for treating cancer or agent for treating cancer are not particularly limited, and include brain tumor (including pituitary adenoma and glioma), head and neck cancer, neck cancer, jaw cancer, maxillary cancer, submandibular gland cancer, mouth cancer (including tongue cancer, floor of mouth cancer, gum cancer, buccal mucosa cancer and hard palate cancer), salivary gland cancer, sublingual gland cancer, parotid gland cancer, nasal cavity cancer, paranasal sinus cancer (including maxillary sinus cancer, frontal sinus cancer, ethmoid sinus cancer and sphenoid sinus cancer), laryngeal cancer (including supraglottic cancer, glottis cancer and subglottic cancer), esophageal cancer, pulmonary cancer (including bronchogenic cancer, non-small-cell lung cancer (including lung adenocarcinoma, squamous cell carcinoma and large-cell lung cancer), small cell lung cancer (including oat cell carcinoma (lymphocyte-like type) and intermediate cell type, mixed small-cell and large cell lung cancer)), breast cancer, pancreatic cancer (including pancreatic ductal carcinoma), gastric cancer (including scirrhous gastric cancer and undifferentiated gastric cancer), biliary tract cancer (including cholangiocarcinoma and gallbladder cancer), small intestine or duodenum cancer, colorectal cancer (including colon cancer, rectal cancer, cecal cancerm, sigmoid colon cancer, ascending colon cancer, transverse colon cancer, descending colon cancer), bladder cancer, renal cancer (including renal cell carcinoma), hepatic cancer (including hepatocellular carcinoma, intrahepatic bile duct cancer), prostate cancer, uterine cancer (including cervical cancer, endometrial cancer), ovarian cancer, thyroid cancer, pharyngeal cancer (including nasopharyngeal carcinoma, oropharyngeal cancer, hypopharyngeal cancer), sarcoma (including osteosarcoma, chondrosarcoma, Kaposi&#39;s sarcoma, myosarcoma, angiosarcoma, fiber sarcoma), malignant lymphoma (including Hodgkin&#39;s lymphoma, non-Hodgkin&#39;s lymphoma), leukemia (including chronic myelogenous leukemia (CML), acute myeloid leukemia (AML), chronic lymphoblastic leukemia (CLL) and acute lymphoblastic leukemia (ALL), including such as lymphoma, multiple myeloma (MM), myelodysplastic-myeloproliferative disease), skin cancer (including basal cell carcinoma, squamous cell carcinoma, malignant melanoma, mycosis fungoides, Sezary syndrome, actinic keratosis, Bowen&#39;s disease, Paget&#39;s disease), and melanoma. 
     
    
     DESCRIPTION OF THE PREFERRED EMBODIMENTS 
       [0095]    The symbols and terms as used herein will be defined and the present invention will be described in details below. 
         [0096]    Several of the structural formulas for the compounds throughout the present specification represent only one isomeric form for convenience, but the invention encompasses any and all of the geometric isomers as well as optical isomers based on asymmetric carbons, stereoisomers and tautomers, and mixtures of those isomers, which are implied by the structures of the compounds, without being limited to any of the formulas shown for convenience. The compounds of the invention therefore include all those having asymmetric carbons therein and existing in optically active or racemic form, with no particular restrictions on the invention. There are also no restrictions when polymorphic crystalline forms thereof exist, and the compounds may be in one crystalline form or a mixture of different crystalline forms, while anhydrates and hydrates of the compounds of the invention are also included. 
         [0097]    The so-called metabolite, a compound which a compound according to the present invention is metabolized in a living body through oxidation, reduction, hydrolysis, conjugation and the others to provide, and the so-called prodrug, a compound which is metabolized in a living body through oxidation, reduction, hydrolysis, conjugation and the others to provide a compound according to the present invention, are also included within the claimed scope of the present invention. 
         [0098]    The “salt” includes a salt of an inorganic acid, a salt of an organic acid, a salt of an inorganic base, a salt of an organic base and a salt of an acidic or basic amino acid, among them, a pharmacologically acceptable salt is preferable. 
         [0099]    The preferable salt of an inorganic acid includes, for example, a salt of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid and phosphoric acid. The preferable salt of an organic acid includes, for example, a salt of acetic acid, succinic acid, fumaric acid, maleic acid, tartaric acid, citric acid, lactic acid, stearic acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, and p-toluenesulfonic acid. 
         [0100]    The preferable salt of an inorganic base includes, for example, an alkali metal salt such as sodium salt and potassium salt, an alkali earth metal salt such as calcium salt and magnesium salt, aluminum salt, and ammonium salt. The preferable salt of an organic base includes, for example, a salt of diethylamine, diethanolamine, meglumine, and N,N-dibenzylethylenediamine. 
         [0101]    The preferable salt of an acidic amino acid includes, for example, a salt of aspartic acid and glutamic acid. The preferable salt of a basic amino acid includes, for example, a salt of arginine, lysine and ornithine. 
         [0102]    The “halogen” represents fluorine, chlorine, bromine or iodine. 
         [0103]    The “C 1-6  alkyl” represents an alkyl of straight or branched chain having a carbon number of 1 to 6, and includes, for specific example, methyl, ethyl, 1-propyl (n-propyl), 2-propyl (i-propyl), 2-methyl-1-propyl (1-butyl), 2-methyl-2-propyl (t-butyl), 1-butyl (n-butyl), 2-butyl (s-butyl), 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 2,2-dimethyl-1-propyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2-methyl-3-pentyl, 3-methyl-3-pentyl, 2,3-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2,2-dimethyl-1-butyl, 2-ethyl-1-butyl, 3,3-dimethyl-2-butyl, and 2,3-dimethyl-2-butyl. 
         [0104]    The “C 2-6  alkenyl” represents an alkenyl of straight or branched chain having one double bond and a carbon number of 2 to 6, and includes, for specific example, ethenyl (vinyl), 1-propenyl, 2-propenyl (allyl), 1-butenyl, 2-butenyl, 3-butenyl, pentenyl, and hexenyl. 
         [0105]    The “C 3-6  alkenyl” represents an alkenyl of straight or branched chain having one double bond and a carbon number of 3 to 6, and includes, for specific example, 2-propenyl (allyl), 2-butenyl, 3-butenyl, pentenyl, and hexenyl. 
         [0106]    The “C 2-6  alkynyl” represents an alkynyl of straight or branched chain having one triple bond and a carbon number of 2 to 6, and includes, for specific example, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, pentynyl, and hexynyl. 
         [0107]    The “C 3-6  alkynyl” represents an alkynyl of straight or branched chain having one triple bond and a carbon number of 3 to 6, and includes, for specific example, 2-propynyl, 2-butynyl, 3-butynyl, pentynyl, and hexynyl. 
         [0108]    The “C 1-6  alkylene” represents a divalent group derived by eliminating further any one hydrogen from the “C 1-6  alkyl” defined above, and includes, for specific example, methylene, 1,2-ethylene, 1,1-ethylene, 1,3-propylene, tetramethylene, pentamethylene, and hexamethylene. 
         [0109]    The “C 3-10  cycloalkyl” represents a mono- or di-cyclic saturated aliphatic hydrocarbon group having a carbon number of 3 to 10, and includes, for specific example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, bicyclo[2.1.0]pentyl, bicyclo[3.1.0]hexyl, bicyclo[2.1.1]hexyl, bicyclo[4.1.0]heptyl, bicyclo[2.2.1]heptyl (norbornyl), bicyclo[3.3.0]octyl, bicyclo[3.2.1]octyl, bicyclo[2.2.2]octyl, bicyclo[4.3.0]nonyl, bicyclo[3.3.1]nonyl, bicyclo[4.4.0]decyl (decalyl), and bicyclo[3.3.2]decyl. 
         [0110]    The “C 6-10  aryl” represents an aromatic hydrocarbon ring group having a carbon number of 6 to 10, and includes, for specific example, phenyl, 1-naphthyl, 2-naphthyl, indenyl, azulenyl, and heptalenyl. 
         [0111]    The “heteroatom” represents nitrogen, oxygen, or sulfur. 
         [0112]    The “5- to 10-membered heteroaryl” represents an aromatic ring group having 5 to 10 atoms forming the ring and containing 1 to 5 heteroatoms, and includes, for specific example, furyl, thienyl, pyrrolyl, imidazolyl, triazolyl, tetrazolyl, thiazolyl, pyrazolyl, oxazolyl, isoxazolyl, isothiazolyl, furazanyl, thiadiazolyl, oxadiazolyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, triazinyl, purinyl, pteridinyl, quinolyl, isoquinolyl, naphthylidinyl, quinoxalinyl, cinnolinyl, quinazolinyl, phthalazinyl, imidazopyridyl, imidazothiazolyl, imidazoxazolyl, benzothiazolyl, benzoxazolyl, benzimidazolyl, indolyl, isoindolyl, indazolyl, pyrrolopyridyl, thienopyridyl, furopyridyl, benzothiadiazolyl, benzoxadiazolyl, pyridopyrimidinyl, benzofuryl, benzothienyl, and thienofuryl. 
         [0113]    The preferable example of the “5- to 10-membered heteroaryl” includes furyl, thienyl, pyrrolyl, imidazolyl, thiazolyl, pyrazolyl, oxazolyl, isoxazolyl, isothiazolyl, pyridyl, and pyrimidinyl. 
         [0114]    The “3- to 10-membered non-aromatic heterocyclic group” represents 
         [0000]    (1) a monocyclic or a bicyclic non-aromatic heterocyclic group
 
(2) having 3 to 10 atoms in the ring,
 
(3) containing 1 to 2 heteroatoms among the atoms of the ring,
 
(4) optionally containing 1 to 2 double bonds in the ring,
 
(5) optionally containing 1 to 3 carbonyl, sulfinyl, or sulfonyl in the ring.
 
         [0115]    If the group contains nitrogen in the ring, the nitrogen may have a bond not participating in the formation of the ring. The group includes, for specific example, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, azepanyl, azocanyl, piperazinyl, diazepanyl, diazocanyl, diazabicyclo[2.2.1]heptyl, morpholinyl, thiomorpholinyl, 1,1-dioxothiomorpholinyl, oxiranyl, oxetanyl, tetrahydrofuryl, tetrahydropyranyl, dioxanyl, tetrahydrothienyl, tetrahydrothiopyranyl, oxazolidinyl, and thiazolidinyl. 
         [0116]    The preferable example of the “3- to 10-membered non-aromatic heterocyclic group” includes aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, azepanyl, piperazinyl, diazepanyl, morpholinyl, thiomorpholinyl, 1,1-dioxothiomorpholinyl, tetrahydrofuryl, and tetrahydropyranyl. 
         [0117]    The “4- to 10-membered non-aromatic heterocyclic group” represents 
         [0000]    (1) a monocyclic or a bicyclic non-aromatic heterocyclic group
 
(2) having 4 to 10 atoms in the ring,
 
(3) containing 1 to 2 heteroatoms among the atoms of the ring,
 
(4) optionally containing 1 to 2 double bonds in the ring,
 
(5) optionally containing 1 to 3 carbonyl, sulfinyl, or sulfonyl in the ring.
 
         [0118]    If the group contains nitrogen in the ring, the nitrogen may have a bond not participating in the formation of the ring. The group includes, for specific example, azetidinyl, pyrrolidinyl, piperidinyl, azepanyl, azocanyl, piperazinyl, diazepanyl, diazocanyl, diazabicyclo[2.2.1]heptyl, morpholinyl, thiomorpholinyl, 1,1-dioxothiomorpholinyl, oxetanyl, tetrahydrofuryl, tetrahydropyranyl, dioxanyl, tetrahydrothienyl, tetrahydrothiopyranyl, oxazolidinyl, and thiazolidinyl. 
         [0119]    The preferable example of the “4- to 10-membered non-aromatic heterocyclic group” includes azetidinyl, pyrrolidinyl, piperidinyl, azepanyl, piperazinyl, diazepanyl, morpholinyl, thiomorpholinyl, 1,1-dioxothiomorpholinyl, tetrahydrofuryl, and tetrahydropyranyl. 
         [0120]    The “C 3-10  cycloalkyl-C 1-6  alkyl” represents a group obtained by substituting any one hydrogen of the above defined “C 1-6  alkyl” with the above defined “C 3-10  cycloalkyl”, and includes, for specific example, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cycloheptylmethyl, cyclooctylmethyl, cyclononylmethyl, cyclodecylmethyl, bicyclo[2.2.1]heptylmethyl (norbornylmethyl), and bicyclo[4.4.0]decylmethyl (decarylmethyl). 
         [0121]    The “C 6-10  aryl-C 1-6  alkyl” represents a group obtained by substituting any one hydrogen of the above defined “C 1-6  alkyl” with the above defined “C 6-10  aryl”, and includes, for specific example, benzyl, 1-naphthylmethyl, 2-naphthylmethyl, phenethyl, 1-naphthylethyl, and 2-naphthylethyl. 
         [0122]    The “5- to 10-membered heteroaryl-C 1-6  alkyl” represents a group obtained by substituting any one hydrogen of the above defined “C 1-6  alkyl” with the above defined “5- to 10-membered heteroaryl”, and includes, for specific example, furylmethyl, thienylmethyl, pyrrolylmethyl, imidazolylmethyl, triazolylmethyl, tetrazolylmethyl, thiazolylmethyl, pyrazolylmethyl, oxazolylmethyl, isoxazolylmethyl, isothiazolylmethyl, furazanylmethyl, thiadiazolylmethyl, oxadiazolylmethyl, pyridylmethyl, pyrazinylmethyl, pyridazinylmethyl, pyrimidinylmethyl, triazinylmethyl, furyl ethyl, thienylethyl, pyrrolylethyl, imidazolyl ethyl, triazolylethyl, tetrazolylethyl, thiazolylethyl, pyrazolylethyl, oxazolylethyl, isoxazolylethyl, isothiazolylethyl, furazanylethyl, thiadiazolylethyl, oxadiazolylethyl, pyridylethyl, pyrazinylethyl, pyridazinylethyl, pyrimidinylethyl, and triazinylethyl. 
         [0123]    The preferable example of the “5- to 10-membered heteroaryl C 1-6  alkyl” includes furylmethyl, thienylmethyl, pyrrolylmethyl, imidazolylmethyl, thiazolylmethyl, pyrazolylmethyl, oxazolylmethyl, isoxazolylmethyl, isothiazolylmethyl, pyridylmethyl, pyrimidinylmethyl, furylethyl, thienylethyl, pyrrolylethyl, imidazolylethyl, thiazolylethyl, pyrazolylethyl, oxazolylethyl, isoxazolylethyl, isothiazolylethyl, pyridylethyl, and pyrimidinylethyl. 
         [0124]    The “3- to 10-membered non-aromatic heterocyclic-C 1-6  alkyl” represents a group obtained by substituting any one hydrogen of the above defined “C 1-6  alkyl” with the above defined “3- to 10-membered heterocyclic group”, and includes, for specific example, aziridinylmethyl, azetidinylmethyl, pyrrolidinylmethyl, piperidinylmethyl, azepanylmethyl, azocanylmethyl, piperazinylmethyl, diazepanylmethyl, diazocanylmethyl, morpholinylmethyl, thiomorpholinylmethyl, 1,1-dioxothiomorpholinylmethyl, oxiranylmethyl, oxetanylmethyl, tetrahydrofurylmethyl, tetrahydropyranylmethyl, dioxanylmethyl, tetrahydrothienylmethyl, tetrahydrothiopyranylmethyl, oxazolidinylmethyl, thiazolidinylmethyl, aziridinylethyl, azetidinylethyl, pyrrolidinylethyl, piperidinylethyl, azepanylethyl, azocanylethyl, piperazinylethyl, diazepanylethyl, diazocanylethyl, morpholinylethyl, thiomorpholinylethyl, 1,1-dioxothiomorpholinylethyl, oxiranylethyl, oxetanyl ethyl, tetrahydrofuryl ethyl, tetrahydropyranylethyl, dioxanylethyl, tetrahydrothienylethyl, tetrahydrothiopyranylethyl, oxazolidinylethyl, and thiazolidinylethyl. 
         [0125]    The preferable example of the “3- to 10-membered non-aromatic heterocyclic-C 1-6  alkyl” includes azetidinylmethyl, pyrrolidinylmethyl, piperidinylmethyl, azepanylmethyl, piperazinylmethyl, diazepanylmethyl, morpholinylmethyl, thiomorpholinylmethyl, tetrahydrofurylmethyl, azetidinylethyl, pyrrolidinylethyl, piperidinylethyl, azepanylethyl, piperazinylethyl, diazepanylethyl, morpholinylethyl, thiomorpholinylethyl, and tetrahydrofurylethyl. 
         [0126]    The “C 1-6  alkoxy” represents a group obtained by adding oxygen to the terminal of the above defined “C 1-6  alkyl”, and includes, for specific example, methoxy, ethoxy, 1-propoxy (n-propoxy), 2-propoxy (1-propoxy), 2-methyl-1-propoxy (1-butoxy), 2-methyl-2-propoxy (t-butoxy), 1-butoxy (n-butoxy), 2-butoxy (s-butoxy), 1-pentyloxy, 2-pentyloxy, 3-pentyloxy, 2-methyl-1-butoxy, 3-methyl-1-butoxy, 2-methyl-2-butoxy, 3-methyl-2-butoxy, 2,2-dimethyl-1-propoxy, 1-hexyloxy, 2-hexyloxy, 3-hexyloxy, 2-methyl-1-pentyloxy, 3-methyl-1-pentyloxy, 4-methyl-1-pentyloxy, 2-methyl-2-pentyloxy, 3-methyl-2-pentyloxy, 4-methyl-2-pentyloxy, 2-methyl-3-pentyloxy, 3-methyl-3-pentyloxy, 2,3-dimethyl-1-butoxy, 3,3-dimethyl-1-butoxy, 2,2-dimethyl-1-butoxy, 2-ethyl-1-butoxy, 3,3-dimethyl-2-butoxy, and 2,3-dimethyl-2-butoxy. 
         [0127]    The “C 1-6  alkylthio” represents a group obtained by adding sulfur to the terminal of the above defined “C 1-6  alkyl”, and includes, for specific example, methylthio, ethylthio, 1-propylthio (n-propylthio), 2-propylthio (1-propylthio), 2-methyl-1-propylthio (1-butylthio), 2-methyl-2-propylthio (t-butylthio), 1-butylthio (n-butylthio), 2-butylthio (s-butylthio), 1-pentylthio, 2-pentylthio, 3-pentylthio, 2-methyl-1-butylthio, 3-methyl-1-butylthio, 2-methyl-2-butylthio, 3-methyl-2-butylthio, 2,2-dimethyl-1-propylthio, 1-hexylthio, 2-hexylthio, 3-hexylthio, 2-methyl-1-pentylthio, 3-methyl-1-pentylthio, 4-methyl-1-pentylthio, 2-methyl-2-pentylthio, 3-methyl-2-pentylthio, 4-methyl-2-pentylthio, 2-methyl-3-pentylthio, 3-methyl-3-pentylthio, 2,3-dimethyl-1-butylthio, 3,3-dimethyl-1-butylthio, 2,2-dimethyl-1-butylthio, 2-ethyl-1-butylthio, 3,3-dimethyl-2-butylthio, and 2,3-dimethyl-2-butylthio. 
         [0128]    The “C 3-6  alkenyloxy” represents a group obtained by adding oxygen to the terminal of the above defined “C 3-6  alkenyl”, and includes, for specific example, 2-propenyloxy (allyloxy), 2-butenyloxy, 3-butenyloxy, pentenyloxy, and hexenyloxy. 
         [0129]    The “C 3-6  alkenylthio” represents a group obtained by adding sulfur to the terminal of the above defined “C 3-6  alkenyl”, and includes, for specific example, 2-propenylthio (allylthio), 2-butenylthio, 3-butenylthio, pentenylthio, and hexenylthio. 
         [0130]    The “C 3-6  alkynyloxy” represents a group obtained by adding oxygen to the terminal of the above defined “C 3-6  alkynyl”, and includes, for specific example, 2-propynyloxy, 2-butynyloxy, 3-butynyloxy, pentynyloxy, and hexynyloxy. 
         [0131]    The “C 3-6  alkynylthio” represents a group obtained by adding sulfur to the terminal of the above defined “C 3-6  alkynyl”, and includes, for specific example, 2-propynylthio, 2-butynylthio, 3-butynylthio, pentynylthio, and hexynylthio. 
         [0132]    The “C 3-10  cycloalkoxy” represents a group obtained by adding oxygen to the terminal of the above defined “C 3-10  cycloalkyl”, and includes, for specific example, cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy, and cyclooctyloxy. 
         [0133]    The “C 3-10  cycloalkylthio” represents a group obtained by adding sulfur to the terminal of the above defined “C 3-10  cycloalkyl”, and includes, for specific example, cyclopropylthio, cyclobutylthio, cyclopentylthio, cyclohexylthio, cycloheptylthio, and cyclooctylthio. 
         [0134]    The “C 6-10  aryloxy” represents a group obtained by adding oxygen to the terminal of the above defined “C 6-10  aryl”, and includes, for specific example, phenoxy, 1-naphthoxy, 2-naphthoxy, indenyloxy, azulenyloxy, and heptalenyloxy. 
         [0135]    The “C 6-10  arylthio” represents a group obtained by adding sulfur to the terminal of the above defined “C 6-10  aryl”, and includes, for specific example, phenylthio, 1-naphthylthio, 2-naphthylthio, indenylthio, azulenylthio, and heptalenylthio. 
         [0136]    The “5- to 10-membered heteroaryloxy” represents a group obtained by adding oxygen to the terminal of the above defined “5- to 10-membered heteroaryl”, and includes, for specific example, furyloxy, thienyloxy, pyrrolyloxy, imidazolyloxy, triazolyloxy, thiazolyloxy, pyrazolyloxy, oxazolyloxy, isoxazolyloxy, isothiazolyloxy, furazanyloxy, thiadiazolyloxy, oxadiazolyloxy, pyridyloxy, pyrazinyloxy, pyridazinyloxy, pyrimidinyloxy, and triazinyloxy. 
         [0137]    The “5- to 10-membered heteroarylthio” represents a group obtained by adding sulfur to the terminal of the above defined “5- to 10-membered heteroaryl”, and includes, for specific example, furylthio, thienylthio, pyrrolylthio, imidazolylthio, triazolylthio, thiazolylthio, pyrazolylthio, oxazolylthio, isoxazolylthio, isothiazolylthio, furazanylthio, thiadiazolylthio, oxadiazolylthio, pyridylthio, pyrazinylthio, pyridazinylthio, pyrimidinylthio, and triazinylthio. 
         [0138]    The “4- to 10-membered non-aromatic heterocyclicoxy group” represents a group obtained by adding oxygen to the terminal of the above defined “4- to 10-membered non-aromatic heterocyclic group”, and includes, for specific example, azetidinyloxy, pyrrolidinyloxy, piperidinyloxy, azepanyloxy, azocanyloxy, piperazinyloxy, diazepanyloxy, diazocanyloxy, morpholinyloxy, thiomorpholinyloxy, 1,1-dioxothiomorpholinyloxy, oxetanyloxy, tetrahydrofuryloxy, tetrahydropyranyloxy, tetrahydrothienyloxy, and tetrahydrothiopyranyloxy. 
         [0139]    The “4- to 10-membered non-aromatic heterocyclicthio group” represents a group obtained by adding sulfur to the terminal of the above defined “4- to 10-membered non-aromatic heterocyclic group”, and includes, for specific example, azetidinylthio, pyrrolidinylthio, piperidinylthio, azepanylthio, azocanylthio, piperazinylthio, diazepanylthio, diazocanylthio, oxetanylthio, tetrahydrofurylthio, tetrahydropyranylthio, tetrahydrothienylthio, and tetrahydrothiopyranylthio. 
         [0140]    The “mono-C 1-6  alkylamino” represents a group obtained by substituting one hydrogen of amino with the above defined “C 1-6  alkyl”, and includes, for specific example, methylamino, ethylamino, 1-propylamino (n-propylamino), 2-propylamino (i-propylamino), 2-methyl-1-propylamino (1-butylamino), 2-methyl-2-propylamino (t-butylamino), 1-butylamino (n-butylamino), 2-butylamino (s-butylamino), 1-pentylamino, 2-pentylamino, 3-pentylamino, 2-methyl-1-butylamino, 3-methyl-1-butylamino, 2-methyl-2-butylamino, 3-methyl-2-butylamino, 2,2-dimethyl-1-propylamino, 1-hexylamino, 2-hexylamino, 3-hexylamino, 2-methyl-1-pentylamino, 3-methyl-1-pentylamino, 4-methyl-1-pentylamino, 2-methyl-2-pentylamino, 3-methyl-2-pentylamino, 4-methyl-2-pentylamino, 2-methyl-3-pentylamino, 3-methyl-3-pentylamino, 2,3-dimethyl-1-butylamino, 3,3-dimethyl-1-butylamino, 2,2-dimethyl-1-butylamino, 2-ethyl-1-butylamino, 3,3-dimethyl-2-butylamino, and 2,3-dimethyl-2-butylamino. 
         [0141]    The “mono-C 3-10  cycloalkylamino” represents a group obtained by substituting one hydrogen of amino with the above defined “C 3-10  cycloalkyl”, and includes, for specific example, cyclopropylamino, cyclobutylamino, cyclopentylamino, cyclohexylamino, cycloheptylamino, and cyclooctylamino. 
         [0142]    The “mono-C 6-10  arylamino” represents a group obtained by substituting one hydrogen of amino with the above defined “C 6-10  aryl”, and includes, for specific example, phenylamino, 1-naphthylamino, 2-naphthylamino, indenylamino, azulenylamino, and heptalenylamino. 
         [0143]    The “mono-5- to 10-membered heteroarylamino” represents a group obtained by substituting one hydrogen of amino with the above defined “5- to 10-membered heteroaryl”, and includes, for specific example, furylamino, thienylamino, pyrrolylamino, imidazolylamino, triazolylamino, tetrazolylamino, thiazolylamino, pyrazolylamino, oxazolylamino, isoxazolylamino, isothiazolylamino, furazanylamino, thiadiazolylamino, oxadiazolylamino, pyridylamino, pyrazinylamino, pyridazinylamino, pyrimidinylamino, and triazinylamino. 
         [0144]    The preferable example of the “mono-5- to 10-membered heteroarylamino” includes furylamino, thienylamino, pyrrolylamino, imidazolylamino, thiazolylamino, pyrazolylamino, oxazolylamino, isoxazolylamino, isothiazolylamino, pyridylamino, and pyrimidinylamino. 
         [0145]    The “mono-4- to 10-membered non-aromatic heterocyclic amino” represents a group obtained by substituting one hydrogen of amino with the above defined “4- to 10-membered non-aromatic heterocyclic group”, and includes, for specific example, azetidinylamino, pyrrolidinylamino, piperidinylamino, azepanylamino, azocanylamino, piperazinylamino, diazepanylamino, diazocanylamino, morpholinylamino, thiomorpholinylamino, 1,1-dioxothiomorpholinylamino, oxetanylamino, tetrahydrofurylamino, tetrahydropyranylamino, tetrahydrothienylamino, and tetrahydrothiopyranylamino. 
         [0146]    The preferable example of the “mono-4- to 10-membered non-aromatic heterocyclic amino” includes pyrrolidinylamino, piperidinylamino, azepanylamino, piperazinylamino, diazepanylamino, morpholinylamino, thiomorpholinylamino, and tetrahydrofurylamino. 
         [0147]    The “di-C 1-6  alkylamino” represents a group obtained by substituting two hydrogen of amino with the same or different groups of the above defined “C 1-6  alkyl”, and includes, for specific example, N,N-dimethylamino, N,N-diethylamino, N,N-di-n-propylamino, N,N-di-1-propyl amino, N,N-di-n-butylamino, N,N-di-1-butylamino, N,N-di-s-butylamino, N,N-di-t-butylamino, N-ethyl-N-methylamino, N-n-propyl-N-methylamino, N-i-propyl-N-methylamino, N-n-butyl-N-methylamino, N-i-butyl-N-methylamino, N-s-butyl-N-methylamino, and N-t-butyl-N-methylamino. 
         [0148]    Each of the substituents in the compound of the present invention represented by the above formula (I) will be described below. 
         [0149]    (Meaning of R 1 ) 
         [0150]    R 1  represents a 3- to 10-membered non-aromatic heterocyclic group wherein the group is limited to a group having nitrogen as a ring constituent atom and the nitrogen having a bonding hand, or a group represented by the formula —NR 11a R 11b , wherein R 11a  and R 11b  may be the same or different and each represents hydrogen, C 1-6  alkyl, C 3-6  alkenyl, C 3-6  alkynyl, C 3-10  cycloalkyl, C 6-10 -aryl, 5- to 10-membered heteroaryl or a 4- to 10-membered non-aromatic heterocyclic group, and R 11a  and R 11b  may be substituted with a substituent selected from Substituent Group A or Substituent Group B. 
         [0151]    R 1  may be substituted with a substituent selected from Substituent Group A or Substituent Group B. 
         [0152]    The preferable example of R 1  includes a group represented by the formula (II): 
         [0000]    
       
                 
         
             
             
         
       
     
         [0000]    wherein a represents an integer of 1 to 4;
 
a group represented by the formula (III):
 
         [0000]    
       
                 
         
             
             
         
       
     
         [0000]    wherein b represents an integer of 1 to 3, and Z represents oxygen, sulfur, carbonyl, sulfonyl, or a group represented by the formula —NR Z —, wherein R Z  represents hydrogen or C 1-6  alkyl, and the groups represented by the formula (II) or (III) may be substituted with a substituent selected from Substituent Group A or Substituent Group B; or
 
a group represented by the formula —NR 11c R 11d , wherein R 11c  represents hydrogen or C 1-6  alkyl, and R 11d  represents C 1-6  alkyl or a group represented by the formula (IV):
 
         [0000]    
       
                 
         
             
             
         
       
     
         [0000]    wherein c represents an integer of 1 to 3, and Z 1  represents oxygen, sulfur, carbonyl, sulfonyl or a group represented by the formula —NR Z1 —, wherein R Z1  represents hydrogen or C 1-6  alkyl, and R 11d  may be substituted with a substituent selected from Substituent Group A or Substituent Group B. 
         [0153]    The more preferable example of R 1  includes azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, piperazin-1-yl, diazepan-1-yl, morpholin-4-yl, thiomorpholin-4-yl, 1,1-dioxothiomorpholin-4-yl, or a group represented by the formula —NR 11e R 11f  wherein R 11e  represents hydrogen or C 1-6  alkyl, R 11f  represents C 1-6  alkyl, pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl or tetrahydropyran-4-yl, and R 11f  may be substituted with a substituent selected from Substituent Group D, and each of the above substituents may be substituted with a substituent selected from Substituent Group D. 
         [0154]    The even more preferable example of R 1  includes azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, piperazin-1-yl, diazepan-1-yl, morpholin-4-yl, and each of the above substituents may be substituted with a substituent selected from Substituent Group E, or a group represented by the formula —NR 11g R 11h  wherein R 11g  represents hydrogen or methyl, R 11h  represents n-propyl, n-butyl, pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl or tetrahydropyran-4-yl, and R 11h  may be substituted with a substituent selected from Substituent Group F. 
         [0155]    The especially preferable example of R 1  includes azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl or piperazin-1-yl, wherein azetidin-1-yl may be substituted with a substituent selected from Substituent Group G and pyrrolidin-1-yl, piperidin-1-yl and piperazin-1-yl are substituted with a substituent selected from Substituent Group G, or a group represented by the formula —N(CH 3 )R 11i  wherein R 11i  represents n-propyl, n-butyl, pyrrolidin-3-yl or piperidin-4-yl, and R 11i  is substituted with a substituent selected from Substituent Group H. 
         [0156]    The most preferable example of R 1  includes azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl or piperazin-1-yl, wherein azetidin-1-yl may be substituted with a substituent selected from Substituent Group G-1 and pyrrolidin-1-yl, piperidin-1-yl and piperazin-1-yl are substituted with a substituent selected from Substituent Group G-1, or azetidin-1-yl having dimethylamino, pyrrolidin-1-yl having dimethylamino or piperidin-1-yl having dimethylamino, a group represented by the formula —N(CH 3 )R 11j  wherein R 11j  represents 1-methylpiperidin-4-yl or 1-ethylpiperidin-4-yl, azetidin-1-yl optionally substituted with a substituent selected from Substituent Group G-2, pyrrolidin-1-yl substituted with a substituent selected from Substituent Group G-2, piperidin-1-yl substituted with a substituent selected from Substituent Group G-2 or a group represented by the formula —N(CH 3 )R 11k , wherein R 11k  represents 3-(dimethylamino)propyl or 1-[2-(dimethylamino)ethyl]piperidin-4-yl. 
         [0157]    The most preferable example of R 1  also includes [2-(dimethylamino)ethyl]piperazin-1-yl, 4-pyrrolidin-1-ylpiperidin-1-yl, 4-[(dimethylamino)methyl]piperidin-1-yl, 4-azetidin-1-ylpiperidin-1-yl, 4-[3-(dimethylamino)azetidin-1-yl]piperidin-1-yl, 4-(4-methylpiperazin-1-yl)piperidin-1-yl, 4-(1-methylpiperidin-4-yl)piperazin-1-yl, 4-(1-methylazetidin-3-yl)piperazin-1-yl, 4-(dimethylamino)piperidin-1-yl, 4-(azetidin-1-ylmethyl)piperidin-1-yl, 4-(pyrrolidin-1-ylmethyl)piperidin-1-yl, (3S)-3-(dimethylamino)pyrrolidin-1-yl, (3R)-3-(dimethylamino)pyrrolidin-1-yl, azetidin-1-yl, pyrrolidin-1-yl, morpholin-4-yl, 4-methylpiperazin-1-yl, 3-hydroxyazetidin-1-yl, 1,3′-biazetidin-1′-yl, 3-(hydroxymethyl)azetidin-1-yl, 3-(dimethylamino)azetidin-1-yl, 3-[(dimethylamino)methyl]azetidin-1-yl, 4-hydroxypiperidin-1-yl, 4-(hydroxymethyl)piperidin-1-yl, (3R)-3-hydroxypyrrolidin-1-yl, (3S)-3-hydroxypyrrolidin-1-yl, 3-(azetidin-1-ylmethyl)azetidin-1-yl, 3-(2-dimethylaminoacetoxy)azetidin-1-yl, methyl(1-methylpiperidin-4-yl)amino, (1-ethylpiperidin-4-yl)(methyl)amino, [3-(dimethylamino)propyl](methyl)amino or {1-[2-(dimethylamino)ethyl]piperidin-4-yl}(methyl)amino. 
         [0158]    (Meaning of Substituent Group A) 
         [0159]    The Substituent Group A represents a group consisting of halogen, hydroxyl, mercapto, nitro, cyano and oxo. 
         [0160]    (Meaning of Substituent Group B) 
         [0161]    The Substituent Group B represents a group consisting of C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 3-10  cycloalkyl, C 6-10 -aryl, 5- to 10-membered heteroaryl, a 3- to 10-membered non-aromatic heterocyclic group, C 1-6  alkoxy, C 3-6  alkenyloxy, C 3-6  alkynyloxy, C 3-10  cycloalkoxy, C 6-10  aryloxy, 5- to 10-membered heteroaryloxy, 4- to 10-membered non-aromatic heterocyclicoxy, C 1-6  alkylthio, C 3-6  alkenylthio, C 3-6  alkynylthio, C 3-10  cycloalkylthio, C 6-10  arylthio, 5- to 10-membered heteroarylthio, 4- to 10-membered non-aromatic heterocyclicthio and a group represented by the formula -T 1 -T 2 -T 3 , wherein T 1  represents a direct bond or C 1-6  alkylene, T 2  represents carbonyl, sulfinyl, sulfonyl, a group represented by the formula —C(═O)—O—, a group represented by the formula —O—C(═O)—, a group represented by the formula —SO 2 —O—, a group represented by the formula —O—SO 2 —, a group represented by the formula —NR T1 —, a group represented by the formula —C(═O)—NR T1 —, a group represented by the formula —NR T1 —C(═O)—, a group represented by the formula —SO 2 —NR T1 — or a group represented by the formula —NR T1 —SO 2 —, T 3  represents hydrogen, C 1-6  alkyl, C 3-6  alkenyl, C 3-6  alkynyl, C 3-10  cycloalkyl, C 6-10  aryl, 5- to 10-membered heteroaryl or a 4- to 10-membered non-aromatic heterocyclic group, and R T1  represents hydrogen or C 1-6  alkyl. 
         [0162]    Each group included in Substituent Group B may be substituted with a substituent selected from Substituent Group C. 
         [0163]    (Meaning of Substituent Group C) 
         [0164]    The Substituent Group C represents a group consisting of halogen, hydroxyl, mercapto, nitro, cyano, oxo, C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 3-10  cycloalkyl, C 6-10  aryl, 5- to 10-membered heteroaryl, a 3- to 10-membered non-aromatic heterocyclic group, C 1-6  alkoxy, C 1-6  alkylthio, mono-C 1-6  alkylamino and di-C 1-6  alkylamino. 
         [0165]    (Meaning of Substituent Group D) 
         [0166]    The Substituent Group D represents a group consisting of halogen, hydroxyl, mercapto, cyano, formyl, oxo, C 1-6  alkyl, C 3-10  cycloalkyl, C 1-6  alkoxy, amino, mono-C 1-6  alkylamino, di-C 1-6  alkylamino, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, diazepanyl and a group represented by -T 4 -T 5 , wherein T 4  represents carbonyl or sulfonyl, and T 5  represents C 1-6  alkyl, C 3-10  cycloalkyl, azetidinyl, pyrrolidinyl, piperidinyl, hydroxyl, C 1-6  alkoxy, amino, mono-C 1-6  alkylamino or di-C 1-6  alkylamino. 
         [0167]    Each group included in Substituent Group D may be substituted with hydroxyl, C 1-6  alkyl, di-C 1-6  alkylamino, azetidinyl or pyrrolidinyl. 
         [0168]    (Meaning of Substituent Group E) 
         [0169]    The Substituent Group E represents a group consisting of methyl, ethyl, dimethylamino, azetidinyl, pyrrolidinyl, piperidinyl and piperazinyl. 
         [0170]    Each group included in Substituent Group E may be substituted with hydroxyl, methyl, dimethylamino, azetidinyl, pyrrolidinyl or piperidinyl. 
         [0171]    (Meaning of Substituent Group F) 
         [0172]    The Substituent Group F represents a group consisting of methyl, ethyl, n-propyl, acetyl, dimethylamino, diethylamino, azetidinyl, pyrrolidinyl and piperazinyl. 
         [0173]    Each group included in Substituent Group F may be substituted with methyl or dimethylamino. 
         [0174]    (Meaning of Substituent Group G) 
         [0175]    The Substituent Group G represents a group consisting of dimethylamino, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, dimethylaminomethyl, dimethylaminoethyl, azetidin-1-ylmethyl, pyrrolidin-1-ylmethyl and piperidin-1-ylmethyl. 
         [0176]    Each group included in Substituent Group G may be substituted with methyl or dimethylamino. 
         [0177]    (Meaning of Substituent Group G-1) 
         [0178]    The Substituent Group G-1 represents a group consisting of azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, dimethylaminomethyl, dimethylaminoethyl, azetidin-1-ylmethyl, pyrrolidin-1-ylmethyl and piperidin-1-ylmethyl. 
         [0179]    Each group included in Substituent Group G-1 may be substituted with methyl or dimethylamino. 
         [0180]    (Meaning of Substituent Group G-2) 
         [0181]    The Substituent Group G-2 represents a group consisting of hydroxyl, methoxy, hydroxymethyl and dimethyl amino acetoxy. 
         [0182]    (Meaning of Substituent Group H) 
         [0183]    The Substituent Group H represents a group consisting of dimethylamino, diethylamino, dimethylaminoethyl, dimethylaminopropyl and 1-methylazetidin-3-yl. 
         [0184]    (Meaning of R 2  and R 3 ) 
         [0185]    R 2  and R 3  represent hydrogen. 
         [0186]    (Meaning of R 4 , R 5 , R 6  and R 7 ) 
         [0187]    R 4 , R 5 , R 6  and R 7  may be the same or different and each represents hydrogen, halogen, hydroxyl, cyano, trifluoromethyl, C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 1-6  alkoxy, amino, mono-C 1-6  alkylamino, di-C 1-6  alkylamino or a group represented by the formula —CO—R 12 , wherein R 12  represents hydrogen, hydroxyl, C 1-6  alkyl, C 1-6  alkoxy, amino, mono-C 1-6  alkylamino or di-C 1-6  alkylamino. 
         [0188]    The preferable example of R 4 , R 5 , R 6  and R 7  includes hydrogen, halogen, C 1-6  alkyl, C 1-6  alkoxy and trifluoromethyl. 
         [0189]    The more preferable example of R 4 , R 5 , R 6  and R 7  includes hydrogen, halogen and C 1-6  alkyl. 
         [0190]    The even more preferable example of R 4 , R 5 , R 6  and R 7  includes hydrogen, fluorine, chlorine and methyl. 
         [0191]    R 4 , R 5 , R 6  and R 7  may be in any one of the following cases: (1) all of them represent hydrogen, (2) all of them represent substituents other than hydrogen, and (3) some of them represent hydrogen and the others represent substituents other than hydrogen. Preferably, 2 to 4 of R 4 , R 5 , R 6  and R 7  represent hydrogen. 
         [0192]    Preferable example for a group represented by the formula: 
         [0000]    
       
                 
         
             
             
         
       
     
         [0000]    includes groups represented by the formulas: 
         [0000]    
       
                 
         
             
             
         
       
     
         [0000]    or a group represented by the formula: 
         [0000]    
       
                 
         
             
             
         
       
     
         [0193]    (Meaning of R 8 ) 
         [0194]    R 8  represents hydrogen or C 1-6  alkyl. 
         [0195]    The preferable example of R 8  includes hydrogen. 
         [0196]    (Meaning of R 9 ) 
         [0197]    R 9  represents a 3- to 10-membered non-aromatic heterocyclic group wherein the group is limited to a group having nitrogen as a ring constituent atom and the nitrogen having a bonding hand, or a group represented by the formula —NR 11a R 11b , wherein R 11a  and R 11b  represent the same meaning as described above. 
         [0198]    R 9  may be substituted with a substituent selected from Substituent Group A or Substituent Group B. 
         [0199]    The preferable example of R 9  includes mono-C 1-6  alkylamino, mono-C 3-10  cycloalkylamino, mono-C 6-10  arylamino, mono-5- to 10-membered heteroarylamino or mono-4- to 10-membered non-aromatic heterocyclic amino, wherein R 9  may be substituted with a substituent selected from Substituent Group A or Substituent Group B. 
         [0200]    The more preferable example of R 9  includes mono-C 3-10  cycloalkylamino or mono-C 6-10  arylamino, wherein R 9  may be substituted with a substituent selected from Substituent Group A or Substituent Group B. 
         [0201]    The even more preferable example of R 9  includes mono-C 3-10  cycloalkylamino or mono-C 6-10  arylamino, wherein R 9  may be substituted with a substituent selected from Substituent Group I. 
         [0202]    The Substituent Group I represents a group consisting of halogen, trifluoromethyl, cyano, C 1-6  alkyl and C 1-6  alkoxy. 
         [0203]    The especially preferable example of R 9  includes cyclopentylamino, cyclohexylamino, cycloheptylamino and phenylamino, wherein R 9  may be substituted with a substituent selected from Substituent Group I. 
         [0204]    The most preferable example of R 9  includes phenylamino optionally substituted with a substituent selected from the above Substituent Group I. 
         [0205]    (Meaning of n) 
         [0206]    n represents an integer of 1 or 2. 
         [0207]    The preferable example of n includes 1. 
         [0208]    (Meaning of X) 
         [0209]    X represents a group represented by the formula —C(R 10 )═ or nitrogen, wherein R 10  represents hydrogen, halogen, cyano, C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl or a group represented by the formula —CO—R 2 , wherein R 12  represents the same meaning as described above. 
         [0210]    The preferable example of X includes a group represented by the formula —C(R 10a )═ or nitrogen, wherein R 10a  represents hydrogen, halogen or cyano. 
         [0211]    The more preferable example of X includes a group represented by the formula —CH═ or nitrogen. 
         [0212]    The preferable compound of the formula (I) includes a compound obtained by selecting respective aspects of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , X and n in the compound and combining them arbitrarily. 
         [0213]    The preferable compound of the formula (I) includes, other than the compounds described in Examples, the compounds illustrated below; but the present invention is not limited to the compounds described in Examples and the compounds illustrated below.
   (1) N-(4-{[2-({[(1-ethylpiperidin-4-yl)(methyl)amino]carbonyl}amino)pyridin-4-yl]oxy}-2-fluorophenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (2) N-(4-{[2-({[(1-ethylpiperidin-4-yl)(methyl)amino]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (3) N-{2-fluoro-4-[(2-{[(4-methyl-1,4-diazepan-1-yl)carbonyl]amino}pyridin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (4) N-(4-fluorophenyl)-N′-{2-fluoro-4-[(2-{[(3-pyrrolidin-1-ylazetidin-1-yl)carbonyl]amino}pyridin-4-yl)oxy]phenyl}cyclopropane-1,1-dicarboxamide,   (5) N-{2-fluoro-4-[(2-{[(4-methylpiperazin-1-yl)carbonyl]amino}pyridin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (6) N-[4-({2-[({4-[2-(dimethylamino)ethyl]-1,4-diazepan-1-yl}carbonyl)amino]pyridin-4-yl}oxy)-2-fluorophenyl]-N′-phenylcyclopropane-1,1-dicarboxamide,   (7) N-(4-{[2-({[3-(dimethylamino)azetidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}-2-fluorophenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (8) N-(4-{[2-({[3-(dimethylamino)azetidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (9) N-(4-{[2-({[3-(dimethylamino)azetidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}-2-fluorophenyl)-N′-phenylcyclopropane-1,1-dicarboxamide,   (10) N-[2-fluoro-4-({2-[({methyl [1-(1-methylazetidin-3-yl)piperidin-4-yl]amino}carbonyl)amino]pyridin-4-yl}oxy)phenyl]-N′-phenylcyclopropane-1,1-dicarboxamide,   (11) N-(2-fluoro-4-{[2-({[4-(1-methylazetidin-3-yl)piperazin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-phenylcyclopropane-1,1-dicarboxamide,   (12) N-(4-fluorophenyl)-N′-(4-{[2-({[4-(1-methylazetidin-3-yl)piperazin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)cyclopropane-1,1-dicarboxamide,   (13) N-(2-fluoro-4-{[2-({[(1-methylpiperidin-4-yl)amino]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (14) N-{2-fluoro-4-[(2-{[(4-hydroxy-1,4′-bipiperidin-1′-yl)carbonyl]amino}pyridin-4-yl)oxy]phenyl}-N′-phenylcyclopropane-1,1-dicarboxamide,   (15) N-(4-{[2-({[{1-[3-(dimethylamino)propyl]piperidin-4-yl}(methyl)amino]carbonyl}amino)pyridin-4-yl]oxy}-2-fluorophenyl)-N′-phenylcyclopropane-1,1-dicarboxamide,   (16) N-(4-{[2-({[(3-azetidin-1-ylpropyl)(methyl)amino]carbonyl}amino)pyridin-4-yl]oxy}-2-fluorophenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (17) N-(2-fluoro-4-{[2-({[methyl(3-pyrrolidin-1-ylpropyl)amino]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (18) N-(4-{[2-({[[3-(dimethylamino)propyl](methyl)amino]carbonyl}amino)pyridin-4-yl]oxy}-2-fluorophenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (19) N-(2-fluoro-4-{[2-({[methyl(4-pyrrolidin-1-ylbutyl)amino]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-phenylcyclopropane-1,1-dicarboxamide,   (20) N-[2-fluoro-4-({2-[(morpholin-4-ylcarbonyl)amino]pyridin-4-yl}oxy)phenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (21) N-[4-({2-[(azetidin-1-ylcarbonyl)amino]pyridin-4-yl}oxy)-2-fluorophenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (22) N-(2-fluoro-4-{[2-({[methyl(3-morpholin-4-ylpropyl)amino]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (23) N-[2-fluoro-4-({2-[({methyl[3-(4-methylpiperazin-1-yl)propyl]amino}carbonyl)amino]pyridin-4-yl}oxy)phenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (24) N-(4-fluorophenyl)-N′-[2-fluoro-4-({2-[(pyrrolidin-1-ylcarbonyl)amino]pyridin-4-yl}oxy)phenyl]cyclopropane-1,1-dicarboxamide,   (25) N-(2-fluoro-4-{[2-({[methyl(1-methylpiperidin-4-yl)amino]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-2-thienylcyclopropane-1,1-dicarboxamide,   (26) N-(2-fluoro-4-{[2-({[methyl(1-methylpiperidin-4-yl)amino]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-1,3-thiazol-2-ylcyclopropane-1,1-dicarboxamide,   (27) N-(2-fluoro-4-{[2-({[methyl(1-methylpiperidin-4-yl)amino]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(5-methylisoxazol-3-yl)cyclopropane-1,1-dicarboxamide,   (28) N-(2-fluoro-4-{[2-({[methyl(1-methylpiperidin-4-yl)amino]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(3-methylisoxazol-5-yl)cyclopropane-1,1-dicarboxamide,   (29) N-{2-fluoro-4-[(2-{[(4-hydroxypiperidin-1-yl)carbonyl]amino}pyridin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (30) N-{2-fluoro-4-[(2-{[(4-methoxypiperidin-1-yl)carbonyl]amino}pyridin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (31) N-{2-fluoro-4-[(2-{[(3-hydroxyazetidin-1-yl)carbonyl]amino}pyridin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (32) N-{2-fluoro-4-[(2-{[(3-methoxyazetidin-1-yl)carbonyl]amino}pyridin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (33) N-(2-fluoro-4-{[2-({[(2-methoxyethyl)(methyl)amino]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (34) N-(2-fluoro-4-{[2-({[4-(3-hydroxyazetidin-1-yl)piperidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (35) N-(2-fluoro-4-{[2-({[methyl(tetrahydro-2H-pyran-4-yl)amino]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (36) N-(2-fluoro-4-{[2-({[methyl(1-methylpiperidin-3-yl)amino]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (37) N-[4-({2-[({3-[(dimethylamino)methyl]piperidin-1-yl}carbonyl)amino]pyridin-4-yl}oxy)phenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (38) N-[4-({2-[({3-[(dimethylamino)methyl]pyrrolidin-1-yl}carbonyl)amino]pyridin-4-yl}oxy)-2-fluorophenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (39) N-(2-fluoro-4-{[2-({[methyl(1-methylpyrrolidin-3-yl)amino]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (40) N-{2-fluoro-4-[(2-{[(3-hydroxypyrrolidin-1-yl)carbonyl]amino}pyridin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (41) N-{2-fluoro-4-[(2-{[(3-methoxypyrrolidin-1-yl)carbonyl]amino}pyridin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (42) N-{4-[(2-{[(3,4-dihydroxypyrrolidin-1-yl)carbonyl]amino}pyridin-4-yl)oxy]-2-fluorophenyl}-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (43) N-{2-fluoro-4-[(2-{[(3-hydroxy-4-methoxypyrrolidin-1-yl)carbonyl]amino}pyridin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (44) N-{4-[(2-{[(3,4-dimethoxypyrrolidin-1-yl)carbonyl]amino}pyridin-4-yl)oxy]-2-fluorophenyl}-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (45) N-{2-fluoro-4-[(2-{[(3-hydroxypiperidin-1-yl)carbonyl]amino}pyridin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (46) N-{2-fluoro-4-[(2-{[(3-methoxypiperidin-1-yl)carbonyl]amino}pyridin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (47) N-(4-{[2-({[3-(dimethylamino)piperidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}-2-fluorophenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide   
 
         [0261]    The more preferable compound of the formula (I) includes the compounds illustrated below;
   (1) N-[4-({2-[({4-[2-(Dimethylamino)ethyl]piperazin-1-yl}carbonyl)amino]pyridin-4-yl}oxy)-2-fluorophenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (2) N-(2-Fluoro-4-{[2-({[methyl(1-methylpiperidin-4-yl)amino]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (3) N-(4-Fluorophenyl)-N′-{2-fluoro-4-[(2-{[(4-pyrrolidin-1-ylpiperidin-1-yl)carbonyl]amino}pyridin-4-yl)oxy]phenyl}cyclopropane-1,1-dicarboxamide,   (4) N-[4-({2-[({4-[(Dimethylamino)methyl]piperidin-1-yl}carbonyl)amino]pyridin-4-yl}oxy)-2-fluorophenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (5) N-{4-[(2-{[(4-Azetidin-1-ylpiperidin-1-yl)carbonyl]amino}pyridin-4-yl)oxy]-2-fluorophenyl}-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (6) N-[4-({2-[({4-[3-(Dimethylamino)azetidin-1-yl]piperidin-1-yl}carbonyl)amino]pyridin-4-yl}oxy)-2-fluorophenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (7) N-(2-Fluoro-4-{[2-({[4-(4-methylpiperazin-1-yl)piperidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (8) N-(2-Fluoro-4-{[2-({[4-(1-methylpiperidin-4-yl)piperazin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (9) N-(2-Fluoro-4-{[2-({[4-(1-methylazetidin-3-yl)piperazin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (10) N-(4-{[2-({[4-(Dimethylamino)piperidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}-2-fluorophenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (11) N-(4-{[2-({[4-(Azetidin-1-ylmethyl)piperidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}-2-fluorophenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (12) N-(4-Fluorophenyl)-N′-(2-fluoro-4-{[2-({[4-(pyrrolidin-1-ylmethyl)piperidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)cyclopropane-1,1-dicarboxamide,   (13) N-(4-{[2-({[(3S)-3-(Dimethylamino)pyrrolidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}-2-fluorophenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (14) N-(4-{[2-({[(3R)-3-(Dimethylamino)pyrrolidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}-2-fluorophenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (15) N-(2-Fluoro-4-{[2-({[methyl(1-methylpiperidin-4-yl)amino]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-phenylcyclopropane-1,1-dicarboxamide,   (16) N-(2-Fluoro-4-{[2-({[4-(4-methylpiperazin-1-yl)piperidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-phenylcyclopropane-1,1-dicarboxamide,   (17) N-[4-({2-[({4-[3-(Dimethylamino)azetidin-1-yl]piperidin-1-yl}carbonyl)amino]pyridin-4-yl}oxy)-2-fluorophenyl]-N′-phenylcyclopropane-1,1-dicarboxamide,   (18) N-(4-{[2-({[(1-Ethylpiperidin-4-yl)(methyl)amino]carbonyl}amino)pyridin-4-yl]oxy}-2-fluorophenyl)-N′-phenylcyclopropane-1,1-dicarboxamide,   (19) N-[4-({2-[(Azetidin-1-ylcarbonyl)amino]pyridin-4-yl}oxy)-2-fluorophenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (20) N-(4-Fluorophenyl)-N′-[2-fluoro-4-({2-[(pyrrolidin-1-ylcarbonyl)amino]pyridin-4-yl}oxy)phenyl]cyclopropane-1,1-dicarboxamide,   (21) N-{2-Fluoro-4-[(2-{[(3-hydroxyazetidin-1-yl)carbonyl]amino}pyridin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (22) N-[4-({2-[(1,3′-Biazetidin-1′-ylcarbonyl)amino]pyridin-4-yl}oxy)-2-fluorophenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (23) N-(2-Fluoro-4-{[2-({[3-(hydroxymethyl)azetidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (24) N-(4-{[2-({[3-(Dimethylamino)azetidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}-2-fluorophenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (25) N-[4-({2-[({3-[(Dimethylamino)methyl]azetidin-1-yl}carbonyl)amino]pyridin-4-yl}oxy)-2-fluorophenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (26) N-{2-Fluoro-4-[(2-{[(4-hydroxypiperidin-1-yl)carbonyl]amino}pyridin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (27) N-(2-Fluoro-4-{[2-({[4-(hydroxymethyl)piperidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (28) N-(2-Fluoro-4-{[2-({[(3R)-3-hydroxypyrrolidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (29) N-(2-Fluoro-4-{[2-({[(3S)-3-hydroxypyrrolidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (30) N-[4-({2-[(Azetidin-1-ylcarbonyl)amino]pyridin-4-yl}oxy)-2,5-difluorophenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (31) N-{2,5-Difluoro-4-[(2-{[(3-hydroxyazetidin-1-yl)carbonyl]amino}pyridin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (32) N-(2,5-Difluoro-4-{[2-({[4-(4-methylpiperazin-1-yl)piperidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (33) N-[2,5-Difluoro-4-({2-[({3-[(dimethylamino)methyl]azetidin-1-yl}carbonyl)amino]pyridin-4-yl}oxy)phenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (34) N-(2,5-Difluoro-4-{[2-({[methyl(1-methylpiperidin-4-yl)amino]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (35) N-{4-[(2-{[3-(Azetidin-1-ylmethyl)azetidin-1-ylcarbonyl]amino}pyridin-4-yl)oxy]-2,5-difluorophenyl}-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (36) N-(2,5-Difluoro-4-{[2-({[3-(hydroxymethyl)azetidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (37) N-{2,5-Difluoro-4-[(4-{[(3-hydroxyazetidin-1-yl)carbonyl]amino}pyrimidin-6-yl)oxy]phenyl}-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (38) N-[4-({4-[({3-[(Dimethylamino)methyl]azetidin-1-yl}carbonyl)amino]pyrimidin-6-yl}oxy)-2,5-difluorophenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (39) N-(2,5-Difluoro-4-{[4-({[3-(hydroxymethyl)azetidin-1-yl]carbonyl}amino)pyrimidin-6-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (40) N-(2,5-Difluoro-4-{[4-({[methyl(1-methylpiperidin-4-yl)amino]carbonyl}amino)pyrimidin-6-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (41) N-(2,5-Difluoro-4-{[4-({[4-(4-methylpiperazin-1-yl)piperidin-1-yl]carbonyl}amino)pyrimidin-6-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (42) N-(4-{[2-({[4-(Dimethylamino)piperidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}-2,5-difluorophenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (43) N-{2,5-Difluoro-4-[(2-{[(4-methylpiperazin-1-yl)carbonyl]amino}pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (44) N-{2,5-Difluoro-4-[(2-{[(4-hydroxypiperidin-1-yl)carbonyl]amino}pyridin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (45) N-{4-[(2-{[(4-Azetidin-1-ylpiperidin-1-yl)carbonyl]amino}pyridin-4-yl)oxy]oxy}-2,5-difluorophenyl}-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (46) N-(2,5-Difluoro-4-{[2-({[3-(2-dimethylaminoacetoxy)azetidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (47) N-(2,5-Difluoro-4-{[2-({[(3S)-3-hydroxypyrrolidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,   (48) N-(2,5-Difluoro-4-{[2-({[(3R)-3-hydroxypyrrolidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.   
 
         [0310]    The still more preferable compound of the formula (I) includes the compounds illustrated below;
   (1) N-(2-Fluoro-4-{[2-({[4-(4-methylpiperazin-1-yl)piperidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide   (2) N-[4-({2-[(Azetidin-1-ylcarbonyl)amino]pyridin-4-yl}oxy)-2-fluorophenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide   (3) N-{2,5-Difluoro-4-[(2-{[(3-hydroxyazetidin-1-yl)carbonyl]amino}pyridin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide   (4) N-(2,5-Difluoro-4-{[2-({[4-(4-methylpiperazin-1-yl)piperidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide   (5) N-(2,5-Difluoro-4-{[2-({[methyl(1-methylpiperidin-4-yl)amino]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide   (6) N-(2,5-Difluoro-4-{[2-({[3-(hydroxymethyl)azetidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.   
 
         [0317]    The phrase “may be substituted with a substituent selected from Substituent Group” or “optionally substituted with a substituent selected from Substituent Group” means “may be substituted with 1 to 3 substituents selected arbitrarily from the substituents described in the Substituent Group.” 
         [0318]    The compounds of the present invention can be produced based on the description of WO 2007/023768. 
       Example 
     Pharmacological Test Example 
       [0319]    WO 2007/023768 has confirmed that the compound of the present invention has inhibitory activity against hepatocyte growth factor receptor, anti-tumor activity, inhibitory activity against angiogenesis, and inhibitory activity against cancer metastasis. The activity against esophageal cancer of the compound of the present invention was evaluated based on the following methods. 
         [0320]    Abbreviations and terms used in the following Pharmacological Test Examples are listed as follows: 
       (Abbreviation List) 
       [0321]    FBS (Fetal bovine serum) 
       Pharmacological Text Example 1 
     An Inhibitory Action Against Proliferation of Human Esophageal Cancer Cells 
       [0322]    Human esophageal cancer cells (OE19, OE21 and OE33) were purchased from Dainippon Sumitomo Pharma Co., Ltd. OE19, OE21 or was suspended in RPMI1640 medium (purchased from Sigma) containing 10% FBS. The cell suspension (2×10 4  cells/ml) was dispensed into a 96-well plate (purchased from FALCON; product No. 353075) by 0.1 ml/well, and incubated at 37° C. in a 5% CO 2  incubator overnight. After the incubation, 0.1 ml of the test substance diluted with RPMI1640 medium containing 10% FBS was added to each well, which was further incubated for 3 days in the 5% CO 2  incubator (37° C.). After the incubation, 10 μl of Cell Counting Kit-8 (purchased from DOJINDO Laboratories) was added to each well, which were incubated for about 2 hours in the 5% CO 2  incubator (37° C.). After the incubation, the absorbance of the each well was measured using a plate reader MTP-500 (Corona Electric Co., Ltd) with a measurement wavelength of 450 nm and a control wavelength of 660 nm. A ratio of absorbance (%) of each well with the test substance against the wells without the test substance was determined, and based on this ratio, the concentration of the test substance required to inhibit 50% of cell proliferation (IC 50 ; μM) was determined and the results are shown in Table 1. 
         [0000]    
       
         
               
               
               
               
             
               
               
               
               
             
           
               
                 TABLE 1 
               
               
                   
               
               
                 Test Substance 
                 0E33 
                 0E19 
                 0E21 
               
               
                   
               
             
             
               
                   
               
             
          
           
               
                 N-(2-Fluoro-4-{[2-({[4-(4-methylpiperazin-1-yl)piperidin-1- 
                 1.6 
                 3.6 
                 5.5 
               
               
                 yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4- 
               
               
                 fluorophenyl)cyclopropane-1,1-dicarboxamide 
               
               
                 N-[4-({2-[(Azetidin-1-ylcarbonyl)amino]pyridin-4-yl}oxy)-2- 
                 0.18 
                 4.2 
                 &gt;10 
               
               
                 fluorophenyl]-N′-(4-fluorophenyl)cyclopropane-1,1- 
               
               
                 dicarboxamide 
               
               
                 N-{2,5-Difluoro-4-[(2-{[(3-hydroxyazetidin-1- 
                 0.24 
                 5.2 
                 6.4 
               
               
                 yl)carbonyl]amino)pyridin-4-yl)oxy]phenyl}-N′-(4- 
               
               
                 fluorophenyl)cyclopropane-1,1-dicarboxamide 
               
               
                 N-(2,5-Difluoro-4-{[2-({[4-(4-methylpiperazin-1-yl)piperidin-1- 
                 0.67 
                 3.5 
                 3.0 
               
               
                 yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4- 
               
               
                 fluorophenyl)cyclopropane-1,1-dicarboxamide 
               
               
                 N-(2,5-Difluoro-4-{[2-({[methyl(1-methylpiperidin-4- 
                 0.14 
                 2.3 
                 1.7 
               
               
                 yl)amino]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4- 
               
               
                 fluorophenyl)cyclopropane-1,1-dicarboxamide 
               
               
                 N-(2,5-Difluoro-4-{[2-({[3-(hydroxymethyl)azetidin-1- 
                 0.25 
                 3.2 
                 7.4 
               
               
                 yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N′-(4- 
               
               
                 fluorophenyl)cyclopropane-1,1-dicarboxamide 
               
               
                   
               
             
          
         
       
     
       INDUSTRIAL APPLICABILITY 
       [0323]    The compound of the present invention has excellent inhibitory action against HGFR and useful as a pharmaceutical composition for treating esophageal cancer.